A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
NCT ID: NCT00596999
Last Updated: 2012-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
6 participants
OBSERVATIONAL
2007-05-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
NCT00897260
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
NCT00295880
Transplantation of Ex-vivo Expanded Cord Blood Stems Cells
NCT01034449
Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation
NCT00737516
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells
NCT01092026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
all subjects will be treated with UCB and HPDSC
UCB and HPDSC
single dose of UCB followed by one unit of HPDSC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UCB and HPDSC
single dose of UCB followed by one unit of HPDSC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* subject requires umbilical cord transplantation
Exclusion Criteria
* major anticipated illness or organ failure incompatible with survival from stem cell transplant
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lolie Yu, MD
Role: PRINCIPAL_INVESTIGATOR
Louisiana State University Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Louisiana State University Children's Hospital
New Orleans, Louisiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCT-HPDSC-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.